Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Assets (2020 - 2026)

Maxcyte has reported Assets over the past 6 years, most recently at $202.5 million for Q4 2025.

  • Quarterly Assets fell 15.44% to $202.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $202.5 million through Dec 2025, down 15.44% year-over-year, with the annual reading at $202.5 million for FY2025, 15.44% down from the prior year.
  • Assets was $202.5 million for Q4 2025 at Maxcyte, down from $213.5 million in the prior quarter.
  • Over five years, Assets peaked at $291.0 million in Q1 2022 and troughed at $93.1 million in Q2 2021.
  • The 5-year median for Assets is $266.7 million (2023), against an average of $250.5 million.
  • Year-over-year, Assets skyrocketed 448.71% in 2021 and then dropped 15.44% in 2025.
  • A 5-year view of Assets shows it stood at $284.1 million in 2021, then increased by 0.89% to $286.7 million in 2022, then decreased by 6.41% to $268.3 million in 2023, then dropped by 10.74% to $239.5 million in 2024, then decreased by 15.44% to $202.5 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Assets are $202.5 million (Q4 2025), $213.5 million (Q3 2025), and $219.8 million (Q2 2025).